Evogene Ltd (EVGN)
0.8199
+0.10
(+13.86%)
USD |
NASDAQ |
May 24, 16:00
0.80
-0.02
(-2.43%)
After-Hours: 20:00
Evogene Enterprise Value: 42.36M for May 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 24, 2024 | 42.36M |
| May 23, 2024 | 37.30M |
| May 22, 2024 | 38.30M |
| May 21, 2024 | 37.55M |
| May 20, 2024 | 35.78M |
| May 17, 2024 | 34.20M |
| May 16, 2024 | 33.76M |
| May 15, 2024 | 35.41M |
| May 14, 2024 | 35.60M |
| May 13, 2024 | 35.32M |
| May 10, 2024 | 35.61M |
| May 09, 2024 | 36.29M |
| May 08, 2024 | 36.51M |
| May 07, 2024 | 36.56M |
| May 06, 2024 | 36.97M |
| May 03, 2024 | 36.79M |
| May 02, 2024 | 36.56M |
| May 01, 2024 | 37.08M |
| April 30, 2024 | 36.23M |
| April 29, 2024 | 33.76M |
| April 26, 2024 | 32.47M |
| April 25, 2024 | 34.17M |
| April 24, 2024 | 34.72M |
| April 23, 2024 | 34.22M |
| April 22, 2024 | 33.73M |
| Date | Value |
|---|---|
| April 19, 2024 | 31.81M |
| April 18, 2024 | 33.26M |
| April 17, 2024 | 35.50M |
| April 16, 2024 | 36.26M |
| April 15, 2024 | 35.57M |
| April 12, 2024 | 38.43M |
| April 11, 2024 | 38.46M |
| April 10, 2024 | 40.07M |
| April 09, 2024 | 41.93M |
| April 08, 2024 | 40.77M |
| April 05, 2024 | 38.37M |
| April 04, 2024 | 38.29M |
| April 03, 2024 | 39.13M |
| April 02, 2024 | 39.13M |
| April 01, 2024 | 40.31M |
| March 31, 2024 | 38.79M |
| March 28, 2024 | 33.90M |
| March 27, 2024 | 33.16M |
| March 26, 2024 | 32.90M |
| March 25, 2024 | 35.88M |
| March 22, 2024 | 36.08M |
| March 21, 2024 | 35.68M |
| March 20, 2024 | 36.45M |
| March 19, 2024 | 36.44M |
| March 18, 2024 | 36.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-17.49M
Minimum
Mar 18 2020
325.33M
Maximum
Feb 11 2021
34.06M
Average
15.22M
Median
Jul 20 2022
Enterprise Value Benchmarks
| Compugen Ltd | 117.14M |
| Pluri Inc | 32.70M |
| BioLine Rx Ltd | 21.54M |
| Can Fite Biofarma Ltd | 3.404M |
| BiomX Inc | -19.27M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.863M |
| Revenue (Quarterly) | 4.19M |
| Total Expenses (Quarterly) | 8.276M |
| EPS Diluted (Quarterly) | -0.08 |
| Gross Profit Margin (Quarterly) | 92.60% |
| Profit Margin (Quarterly) | -92.20% |
| Earnings Yield | -56.10% |
| Normalized Earnings Yield | -56.10 |